ST. LOUIS--(BUSINESS WIRE)--Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced that it has received a Food and Drug Administration (FDA) Office of Generic Drugs grant (#1 U01 FD005225-01) to further develop and validate its Simcyp® Simulator’s mechanistic dermal absorption model, MechDermA. Certara will enhance its physiologically-based pharmacokinetic (PBPK) modeling and simulation platform to assess the bioequivalence of drugs absorbed through the skin, while also factoring in variability in specific populations.
The current model’s capabilities first attracted the scientific community’s attention when they were outlined in a Journal of Pharmaceutical Science paper published in July 2012 that received “Editor’s Pick” status. That abstract is available here.
Help employers find you! Check out all the jobs and post your resume.
The current model’s capabilities first attracted the scientific community’s attention when they were outlined in a Journal of Pharmaceutical Science paper published in July 2012 that received “Editor’s Pick” status. That abstract is available here.
Help employers find you! Check out all the jobs and post your resume.
